Search
ETC-1001
go.drugbank.com/drugs/DB05866ExperimentalETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Bifonazole
go.drugbank.com/drugs/DB04794ApprovedBifonazole is an azole antifungal drug.
Synonyms: 1-[biphenyl-4-yl(phenyl)methyl]imidazoleProducts: MYCOSPOR POLVO AL 1%, BIFONAZOL CREMA AL 1%Delavirdine
go.drugbank.com/drugs/DB00705ApprovedInvestigationalWithdrawnA potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Synonyms: (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide), N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamideCefacetrile
go.drugbank.com/drugs/DB01414InvestigationalVet approvedA derivative of 7-aminocephalosporanic acid.
Propyl Gallate
go.drugbank.com/drugs/DB12450InvestigationalPropyl Gallate is under investigation in clinical trial NCT01450098 (A Study of LY2484595 in Healthy Subjects).
Categories: Compounds used in a research, industrial, or household settingS-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Bacillus calmette-guerin substrain connaught live antigen
go.drugbank.com/drugs/DB10804ApprovedInvestigationalWithdrawnIt is prepared from the Connaught strain of Bacillus Calmette and Guérin. … Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary
AV608
go.drugbank.com/drugs/DB05072InvestigationalAV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
Incadronic acid
go.drugbank.com/drugs/DB06255Experimental[A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.[A202289] … Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.